MedTrace Logo

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

NCT06932068 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2026-05-07

No results posted yet for this study

Summary

This is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma

Conditions

  • HER2 Negative
  • Low PD-L1 Expressing
  • Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

Iparomlimab and Tuvonralimab (QL1706)

5 mg/kg, ivdrip, Day 1, Q3W, until progressive disease or intolerable toxicity.

DRUG

Oxallplation

130 mg/m2, ivdrip, Day 1, Q3W, for the first 6 cycles.

DRUG

Capectitabine Tablets

1000 mg/m2, po, bid, Days 1-14, Q3W, until progressive disease or intolerable toxicity.

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Principal Investigators

  • Lian Liu, MD, PHD · Qilu Hospital of Shandong University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-26
Primary Completion
2026-10-31
Completion
2027-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06932068 on ClinicalTrials.gov